CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Core Viewpoint - CytomX Therapeutics, Inc. has initiated a public offering of $250 million in common stock and pre-funded warrants, with an additional option for underwriters to purchase up to $37.5 million more [1][2]. Group 1: Offering Details - The public offering consists of $250 million in shares of common stock and pre-funded warrants for certain investors [1]. - CytomX plans to grant underwriters a 30-day option to purchase an additional $37.5 million in shares at the public offering price [1]. - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the continued development of Varseta-M and other pipeline programs [2]. - Remaining proceeds will be allocated for capital expenditures, working capital, and general corporate purposes [2]. Group 3: Company Overview - CytomX is a clinical-stage biopharmaceutical company focused on developing conditionally activated, masked PROBODY® therapeutics for cancer treatment [5]. - The company's pipeline includes Varseta-M, a masked ADC targeting EpCAM, and CX-801, a masked interferon alpha-2b PROBODY® cytokine [5]. - Varseta-M is being developed for metastatic colorectal cancer, while CX-801 targets metastatic melanoma [5]. - CytomX has established collaborations with major oncology leaders such as Amgen, Bristol Myers Squibb, Regeneron, and Moderna [5].